DailyMed adds updated labeling for extended-release guaifenesin and pseudoephedrine
DailyMed’s latest label entry for guaifenesin and pseudoephedrine HCl extended-release tablets sets out a familiar respiratory combination in precise regulatory terms: one ingredient loosens mucus, the other constricts swollen nasal blood vessels. The product pairs guaifenesin 600 mg with pseudoephedrine HCl 60 mg in an oral extended-release tablet marketed as a human OTC drug. It is packaged by Rugby Laboratories and manufactured by Ohm Laboratories, with an abbreviated new drug application on file.
The label update is straightforward, but the clinical utility is easy to recognize at the bedside. When upper respiratory infection, allergic rhinitis, or sinus congestion drives thick secretions and blocked airflow, the two-drug design aims at both halves of the symptom burden at once. Guaifenesin is meant to make bronchial secretions less tenacious and easier to clear; pseudoephedrine acts as a nasal decongestant, easing mucosal swelling and helping drainage.
A product like this sits squarely in symptom control, not disease modification. The relief it offers is temporary, and the label keeps that boundary visible.
Mucus clearance and adrenergic decongestion in one tablet
The active ingredients reflect two different pharmacologic targets. Guaifenesin is labeled as an expectorant, intended to loosen phlegm and thin bronchial secretions so cough becomes more productive. Pseudoephedrine HCl is labeled as a nasal decongestant, and its effect is aimed at the vascular congestion that makes the nose and sinuses feel blocked.
This combination is common because it addresses a frequent pairing of symptoms: chest mucus that will not move and upper-airway congestion that makes breathing feel restricted. In practical terms, one drug helps mobilize secretions while the other reduces the vascular fullness that narrows the nasal passages. The resulting effect is not cure, but a measurable reduction in the friction patients feel when they breathe, cough, or sleep with a cold or allergy flare.
The label specifically lists temporary relief of congestion due to the common cold, hay fever, and upper respiratory allergies. It also states that the product temporarily restores freer breathing through the nose, promotes nasal and sinus drainage, and temporarily relieves sinus congestion and pressure.
Warnings point to the patients who need caution, not casual use
The safety language is as clinically important as the active ingredients. The product should not be used with a prescription monoamine oxidase inhibitor, or within 2 weeks of stopping one. That restriction matters because pseudoephedrine is a sympathomimetic decongestant and can interact dangerously with MAOIs.
The label also tells patients to ask a doctor before use if they have heart disease, high blood pressure, thyroid disease, diabetes, trouble urinating from an enlarged prostate gland, a persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, or emphysema, or a cough accompanied by too much phlegm. These are not minor caveats; they identify the people in whom a decongestant can worsen baseline physiology or obscure a more serious respiratory diagnosis.
Pseudoephedrine can increase nervousness, dizziness, and sleeplessness, all effects reflected directly in the stop-use instructions. Patients who develop those symptoms are told to stop the product and ask a doctor if symptoms fail to improve within 7 days, return, or occur with fever, rash, or persistent headache. The label frames those features as possible signs of a serious illness rather than routine cold symptoms.
Pregnant and breast-feeding patients are directed to ask a health professional before use. The label also instructs caregivers to keep the product out of the reach of children and to seek medical help or contact Poison Control immediately in the event of overdose.
Extended-release design shapes dosing and swallowing instructions
The dosage form is not a trivial detail. These are extended-release tablets, and the label says they should not be crushed, chewed, or broken. That instruction protects the release mechanism; altering the tablet can distort how quickly the ingredients are delivered and may change tolerability.
Adults and children 12 years and older are instructed to take 2 extended-release tablets every 12 hours, with a maximum of 4 tablets in 24 hours. Children younger than 12 years should not use the product. The tablets should be taken with a full glass of water, and the label states they may be administered without regard to meals.
The product characteristics are ordinary but useful for identification: the tablets are white to off-white, oval, unscored, and 16 mm in size. The inactive ingredients are carbomer homopolymer type B, magnesium stearate, hypromellose, and microcrystalline cellulose. The packaging information shows 18-count and 36-count blister packs under NDC 0536-1488-21 and NDC 0536-1488-36.
OTC labeling still depends on careful self-screening
Combination cough-and-cold products often seem simple, yet the label reveals how much judgment they require. A patient with a short-lived cold and no major comorbidity may use a decongestant-expectorant pair for symptom relief. A patient with hypertension, arrhythmia risk, urinary retention, hyperthyroidism, or chronic pulmonary symptoms may need a different plan entirely.
Pseudoephedrine’s sympathomimetic action explains much of that caution. By reducing nasal congestion, it may also raise heart rate, worsen insomnia, or intensify jitteriness in susceptible patients. Guaifenesin is generally used to make secretions easier to clear, but the combination should not be viewed as a remedy for chronic cough syndromes, asthma, emphysema, or bronchitis without medical assessment.
The label’s instruction to stop if symptoms persist beyond 7 days or recur with fever, rash, or persistent headache is clinically meaningful because those features move the presentation away from an uncomplicated self-limited upper respiratory illness. In that setting, continued OTC decongestant use risks masking an evolving infection, inflammatory process, or another diagnosis that needs direct evaluation.
Regulatory details anchor the product’s market status
The update identifies the product as an ANDA entry with marketing status tied to abbreviated approval pathways. DailyMed lists October 13, 2026 as the updated label date and October 16, 2026 as the published date for the current version. The presence of the label in the federal drug database confirms the product’s current regulatory footprint, along with the manufacturer, packager, NDCs, and standard OTC directions.
For clinicians, the practical reading is simple: this is a standard extended-release guaifenesin-pseudoephedrine product with clear dosing, clear contraindications around MAOIs, and the usual decongestant cautions in cardiovascular, endocrine, and urologic disease. The label does not add new efficacy claims or new safety signals; it formalizes how the product should be used and where it should not be used.